A Phase 2 interventional study of oral vinorelbine and Capecitabine in Breast Cancer, sponsored by Pierre Fabre Medicament. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-30.
Sponsored by Pierre Fabre Medicament (part of Pierre Fabre) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 100 studies testing vinorelbine in Breast Neoplasms — 5 open to participants now, 8 under way, 1 of them phase 3. Vinorelbine · Breast Neoplasms.
Among the 100 studies testing vinorelbine in Breast Neoplasms, this one is the 17th largest by enrollment of the 97 interventional ones that give a count, is one of 7 that started in 2007, is one of 63 in phase 2, and was the 75th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →5 of the 100 studies testing vinorelbine in Breast Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
European Institute of Oncology · Sites in Italy
Ages 18+
Henan Cancer Hospital · Sites in China
Ages 18+ · Women only
European Institute of Oncology · Sites in Italy
Ages 18–99 · Women only
QIAO LI
Ages 18–75
Fudan University
Ages 18–70 · Women only
By country, each count listing its studies:
Vinorelbine: first FDA approval 1994 (NAVELBINE). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
100 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 71 · Phase 3 12 · Phase 4 3
First in 1997; this study’s year is marked. 7 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 152 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 48 across the 97 interventional studies. Of the 71 that completed or were terminated, 24 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 100 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pierre Fabre Medicament, one of the names counted as Pierre Fabre. Under that name alone:
Pierre Fabre Medicament is the lead sponsor of 73 studies on the registry; 6 are open to participants now.
12 studies in Breast Neoplasms by Pierre Fabre: 1 open now, 2 under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 12 studies in Breast Neoplasms by Pierre Fabre, this one is the only one that started in 2007, is the only one in phase 2, and was the 7th registered.
Pierre Fabre’s Breast Neoplasms studies by the year they started, since 2006.
2 of the studies testing vinorelbine in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06690840European Institute of OncologyAtezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients | 2026-12-15 |
| NCT05296577Henan Cancer HospitalAnlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer | 2027-09-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 100 studies testing vinorelbine in Breast Neoplasms, from their registry updates:
Among Pierre Fabre’s 12 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this international open-label randomized phase II trial is to evaluate the efficacy and safety of an all-oral combination and two all-intravenous combinations as first-line therapy for HER2-negative mBC patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
oral vinorelbine (OV) with capecitabine (CAP)
Drug: oral vinorelbine · Drug: Capecitabine
gemcitabine (GEM) in combination with paclitaxel (PAC)
Drug: Gemcitabine 1250 mg/m² · Drug: Paclitaxel
gemcitabine (GEM) in combination with docetaxel (DOC)
Drug: Gemcitabine 1000 mg/m² · Drug: Docetaxel
Oral vinorelbine 60 mg/m² on day 1 \& day 8, for cycle 1, and then 80 mg/m² on day 1 \& day 8, every 3 weeks for subsequent cycles
Capecitabine 1000 mg/m² twice a day (2000 mg/m² daily) from day 1 to day 14
Drug page: Gemcitabine
Gemcitabine 1250 mg/m² on day 1 \& day 8
Drug page: Gemcitabine
Gemcitabine: 1000 mg/m² on day 1 \& 8
Paclitaxel 175 mg/m² on day 1
Docetaxel 75 mg/m² on day 1
Disease Control Rate (DCR)
Disease control rate (DCR) defined as the sum of complete response, partial response and stable disease for at least 3 months according to RECIST criteria version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR)= Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. Stable disease: no partial response or progression of the disease
Time frame: From Baseline to disease progression or death, up to 6 years
| Milestone | Vinorelbine-Capecitabine (Arm A) | Gemcitabine-Paclitaxel (Arm B) | Gemcitabine-Docetaxel (Arm C) |
|---|---|---|---|
| Started | 51 | 50 | 51 |
| Completed | 0 | 0 | 0 |
| Not completed | 51 | 50 | 51 |
| Withdrew: Progressive disease | 23 | 14 | 7 |
| Withdrew: Protocol violation | 3 | 1 | 2 |
| Withdrew: Drug related toxicity | 7 | 7 | 13 |
| Withdrew: Non drug related toxicity | 3 | 0 | 0 |
| Withdrew: Death | 2 | 2 | 1 |
| Withdrew: Withdrawal by subject | 7 | 6 | 11 |
| Withdrew: Other reason | 6 | 20 | 17 |
Disease control rate (DCR) defined as the sum of complete response, partial response and stable disease for at least 3 months according to RECIST criteria version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR)= Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. Stable disease: no partial response or progression of the disease
| percentage of participants | Vinorelbine-Capecitabine (Arm A) | Gemcitabine-Paclitaxel (Arm B) | Gemcitabine-Docetaxel (Arm C) |
|---|---|---|---|
| Disease Control Rate (DCR) | 73.5 (58.9 to 85.1) | 78.0 (64.1 to 88.5) | 80.0 (66.3 to 90.0) |
Collected over All adverse events were collected from the first dose of treatment through study completion up to 6 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vinorelbine-Capecitabine (Arm A) | 31/49 (63.3%) | 13/49 (26.5%) | 49/49 (100%) |
| Gemcitabine-Paclitaxel (Arm B) | 37/50 (74%) | 16/50 (32%) | 50/50 (100%) |
| Gemcitabine-Docetaxel (Arm C) | 35/50 (70%) | 12/50 (24%) | 50/50 (100%) |
| Event | Vinorelbine-Capecitabine (Arm A) | Gemcitabine-Paclitaxel (Arm B) | Gemcitabine-Docetaxel (Arm C) |
|---|---|---|---|
| VomitingGastrointestinal disorders | 5/49 | 1/50 | 1/50 |
| DiarrhoeaGastrointestinal disorders | 4/49 | 1/50 | 1/50 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/49 | 0/50 | 1/50 |
| NauseaGastrointestinal disorders | 3/49 | 1/50 | 3/50 |
| PyrexiaGeneral disorders | 2/49 | 3/50 | 0/50 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/49 | 3/50 | 0/50 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/49 | 3/50 | 0/50 |
| FatigueGeneral disorders | 0/49 | 3/50 | 1/50 |
| ConstipationGastrointestinal disorders | 2/49 | 0/50 | 0/50 |
| Hip fractureInjury, poisoning and procedural complications | 2/49 | 0/50 | 0/50 |
| Event | Vinorelbine-Capecitabine (Arm A) | Gemcitabine-Paclitaxel (Arm B) | Gemcitabine-Docetaxel (Arm C) |
|---|---|---|---|
| FatigueGeneral disorders | 38/49 | 35/50 | 42/50 |
| AlopeciaSkin and subcutaneous tissue disorders | 12/49 | 38/50 | 40/50 |
| DiarrhoeaGastrointestinal disorders | 29/49 | 13/50 | 19/50 |
| NauseaGastrointestinal disorders | 29/49 | 19/50 | 22/50 |
| VomitingGastrointestinal disorders | 27/49 | 12/50 | 19/50 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 24/49 | 4/50 | 6/50 |
| AnorexiaMetabolism and nutrition disorders | 19/49 | 13/50 | 17/50 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 18/49 | 13/50 | 17/50 |
| Peripheral sensory neuropathyNervous system disorders | 12/49 | 18/50 | 8/50 |
| Abdominal painGastrointestinal disorders | 16/49 | 6/50 | 9/50 |
Baseline characteristics are described for the Intent-to-treat population that consisted of all treated patients
| Age, Continuous(years) | Vinorelbine-Capecitabine (Arm A) | Gemcitabine-Paclitaxel (Arm B) | Gemcitabine-Docetaxel (Arm C) | Total |
|---|---|---|---|---|
| Mean | 56.4 ± 9.7 | 56.0 ± 10.8 | 57.4 ± 9.7 | 56.6 ± 10.0 |
| Sex: Female, Male(Participants) | Vinorelbine-Capecitabine (Arm A) | Gemcitabine-Paclitaxel (Arm B) | Gemcitabine-Docetaxel (Arm C) | Total |
|---|---|---|---|---|
| Female | 49 | 50 | 50 | 149 |
| Male | 0 | 0 | 0 | 0 |
| Body surface area(mg/m²) | Vinorelbine-Capecitabine (Arm A) | Gemcitabine-Paclitaxel (Arm B) | Gemcitabine-Docetaxel (Arm C) | Total |
|---|---|---|---|---|
| Mean | 1.8 ± 0.2 | 1.7 ± 0.2 | 1.8 ± 0.2 | 1.7 ± 0.2 |
| Delay between diagnosis and study entry(years) | Vinorelbine-Capecitabine (Arm A) | Gemcitabine-Paclitaxel (Arm B) | Gemcitabine-Docetaxel (Arm C) | Total |
|---|---|---|---|---|
| Mean | 5.5 ± 5.7 | 5.8 ± 6.3 | 5.8 ± 5.9 | 5.7 ± 5.9 |
| Primary tumour site(Participants) | Vinorelbine-Capecitabine (Arm A) | Gemcitabine-Paclitaxel (Arm B) | Gemcitabine-Docetaxel (Arm C) | Total |
|---|---|---|---|---|
| Bilateral | 3 | 0 | 0 | 3 |
| Left breast | 20 | 24 | 29 | 73 |
| Right breast | 26 | 26 | 21 | 73 |
| Delay between first relapse/progression and study entry(months) | Vinorelbine-Capecitabine (Arm A) | Gemcitabine-Paclitaxel (Arm B) | Gemcitabine-Docetaxel (Arm C) | Total |
|---|---|---|---|---|
| Mean | 8.8 ± 19.1 | 11.1 ± 29.8 | 11.3 ± 23.9 | 10.4 ± 24.5 |
| Categorized number of organs involved at baseline(Participants) | Vinorelbine-Capecitabine (Arm A) | Gemcitabine-Paclitaxel (Arm B) | Gemcitabine-Docetaxel (Arm C) | Total |
|---|---|---|---|---|
| 1 organ | 9 | 3 | 4 | 16 |
| 2 organs | 14 | 25 | 17 | 56 |
| >= 3 organs | 26 | 22 | 29 | 77 |
No study locations are listed for this record.
Ran from Mar 2007 to primary completion in Apr 2013, 72 months.
Results were first posted in Apr 2024, 11 years after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 72 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vinorelbine · Capecitabine · Gemcitabine